


# Preliminary Results

David Stirling: Group CEO Gary McGrath: Group CFO

13 March 2018



AZOTE® ZOTEK® T-FIT® MUCELL®

# Important notice



By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations:

This presentation is being made only in the United Kingdom and this document is being distributed only to and is directed only at persons who have professional experience in matters relating to investments falling within Article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 of the United Kingdom (as amended) (the "FPO") or to whom it may otherwise be lawful to distribute it pursuant to the FPO (all such persons together being referred to as "relevant persons"). Any person who is not a relevant person should not act or rely on this presentation or this document or any of its contents. Any person who is not a relevant person may not attend this presentation and if such person has received any document forming part of this presentation, he should return it immediately.

This document does not constitute or form part of, and should not be construed as, an offer, invitation or inducement to purchase or subscribe for any securities nor shall it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document does not constitute a recommendation by Zotefoams plc ("Zotefoams"), or any of their respective affiliates regarding the securities of Zotefoams.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of Zotefoams or any of its respective directors, officers, partners, employees, agents or advisers or any other person as to the accuracy or completeness of the information or opinions contained in these slides or the presentation and no responsibility or liability is accepted by any of them for any such information or opinions or for any errors, omissions, misstatements, negligence or otherwise for any other communication written or otherwise. Notwithstanding the aforesaid, nothing in this paragraph shall exclude liability for any undertaking, representation, warranty or other assurance made fraudulently.

This presentation contains certain statements that are or may be forward looking with respect to the financial conditions, results of operations and business achievements/performance of Zotefoams. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. While these represent Zotefoams' current judgment on the matters presented, they are subject to certain risks and uncertainties that could cause the actual results to differ materially from those presented. Zotefoams' disclaims any intention or obligation to update these forward looking statements.

Neither this presentation nor any copy of it may be (i) taken or transmitted into the United States of America, (ii) distributed, directly or indirectly, in the United States of America or to any US person (within the meaning of regulations made under the Securities Act 1933, as amended), (iii) taken or transmitted into or distributed in Canada, Australia or the Republic of South Africa or to any resident thereof, or (iv) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this document in other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

These slides are confidential and are being supplied to you solely for your information and may not be reproduced, redistributed or passed to any other person or published in whole or in part for any purpose.

# Positioning & Strategy



# **Business Overview**



### **AUTOCLAVE TECHNOLOGY**



### **POLYOLEFINS**

### **AZOTE®**

Premium, durable, foams Ultra durable, highly heat and impact resistant foam. These foam sheets and blocks are manufactured from common polymers using our unique nitrogen-expansion process.

### Key markets served

Automotive
Aviation
Construction
Industrial
Marine
Military
Packaging
Sport and leisure

### Key market drivers

- 1. Light weighting
- 2. High-technology insulation
- 3. Durability
- 4. Fire safety
- 5. Reduced toxicity

### HPP

### **ZOTEK®**

Lightweight technical foams
Uniformly dense foam sheets
and blocks with a consistent
cell structure. ZOTEK is
manufactured from engineering
polymers using our unique
nitrogen-expansion process.

### Key markets served

Automotive
Aviation
Athletic footwear
Construction
Packaging

### Key market drivers

- 1. Light weighting
- 2. Personal safety
- 3. High-technology insulation
- 4. Durability
- 5. Fire safety
- 6. High-technology insulation
- 7. Reduced toxicity

## T-FIT®

V

### Technical insulation for industry

A range of bacteria resistant insulation products manufactured from high-grade polymers using our unique nitrogen-expansion process. T-FIT® products are purpose designed to perform in demanding environments.

### Key markets served

Food and personal care manufacturing
High temperature processing environments
Pharmaceutical cleanrooms

### Key market drivers

- 1. Aging population
- 2. Durability
- 3. Reduced toxicity

### **EXTRUSION TECHNOLOGY**



### MEL

### MuCell®

# Innovative and accessible technology for greener, lower cost plastic products

This pioneering licensed technology injects gas into plastics during the manufacturing process to create micro-bubbles – the end product uses 15-20% less material than similar plastics but delivers equally high performance.

### Key markets served

Automotive Consumer packaging


### Key market drivers


- Light weighting
- 2. High-technology insulation
- 3. Durability
- 4. Reduced toxicity

# Segment Overview




### Revenue by Geography





### Revenue by Business Unit



A well balanced geographical and industrial spread, with improving mix of higher value HPP business

# **Zotefoams' Strategy**



"We intend to be the world leader in cellular materials technology in our chosen markets"

We deliver stakeholder value by using unique technology to create a portfolio of differentiated products.



We focus
resources primarily
on markets where
we are, or have
the potential to be,
a market leader.

We intend to develop our business through sustained high levels of organic growth and, where appropriate, through partnerships or acquisitions.



# The Year



# Main achievements in period



- √ 7% volume growth though improved utilisation of existing assets
- ✓ Double-digit growth in all business units
- ✓ Completed major US capacity expansion investment, now producing high-quality foam and providing 20% increased global capacity
- ✓ Strategic partnership with Nike to develop footwear technology and supply materials, augmenting HPP growth prospects
- ✓ Captured market share and improved mix benefits in important German market following switch to direct supply into a larger number of customers
- ✓ Launched brand extension of T-FIT® insulation, using a lower-cost manufacturing process targeted at food, dairy and general process industries
- ✓ Increased number of machines in production using MuCell® technology by 46%

### Achievements vs strategic objectives



AZOTE® polyolefin foams up 18%



HPP & MEL 25% of Group revenue, up 37%



Operating margins stable at 13.4%, aggregate segment margins up 50bps to 17.3%



Return on capital (over our investment cycle) up 157 bps to 15.5%

AZOTE® ZOTEK® T-FIT® MuCell® Page : 8

# Strong results



### Revenue

£70.15m + 22% reported

+ 17% constant currency

### **Business Units**

AZOTE ® +18% HPP +32% MuCell® +56%

# Adjusted Operating Profit

£9.70m
+ 20%
before exceptional item
+ 15%
constant currency

# Adjusted EPS

16.64p +14% before exceptional item

### **Gross Margin**

35.3% + 90bps reported

Full Year Dividend

5.93p +3.1%

# Polyolefin Foams



# Common polymers made extraordinary by Zotefoams' unique process, creating premium, durable, consistent materials

### Revenue

- Croydon at full capacity
- 7% volume growth
- 6% price increases and mix improvements
- 5% tailwind through FX
- Market share capture in Germany through successful direct approach to market
- Growth across all regions

Polyolefin Foams	Dec-17 £m	Dec-16 £m	% Change
Group revenue	52.82	44.73	18%
Segment profit pre amortisation	10.29	8.00	29%
Segment profit post amortisation	10.29	7.96	29%
Segment profit margin	19%	18%	

### Costs and Margin

- Euro-denominated LDPE relatively stable
- Labour cost increases modest
- Segment margins up 168bps through price & mix improvement and benefit of operational gearing

- Sales through local channel partners who promote and convert foams
- Mainly a local market due to channel partner profile and transport cost
- Capacity investment on existing site in Walton, KY balances global supply with local demand
- US investment (HP1) completed in February 2018, adding over 20% annualized global capacity
- Board has approved \$9m investment to commission HP2 and ancillary equipment

# MuCell Extrusion

### Revenue

- Further 22 lines installed at licensees, bringing total installed base to 133
- Completion of largest contract in MuCell® history, representing 25% of equipment revenue in year
- Licence and royalty income up 19% to £1.01m
- 46% increase in number of machines in production to 83

# Costs and Margin

- Lower initial margin on equipment revenue, followed by higher margin "licence fee" contract
- Planned investment in people, including dedicated IP Manager
- £0.29m write-down of history as a result of superseded machinery developments

MEL	Dec-17 £m	Dec-16 £m	% Change
Group revenue	4.25	2.73	56%
Segment loss pre amortisation	(1.03)	(0.40)	(158%)
Amortisation	(0.33)	(0.42)	-
Segment loss post amortisation	(1.36)	(0.82)	(66%)

- Expected present value of contracts
  - A key management measure of long-term value creation
  - Increased significantly in the year
- Focus in specific markets
  - Thermoformed sheet (e.g. yoghurt pots)
  - Blow-moulded packaging
  - Film
- Strong IP pipeline

# High-Performance Products (HPP)



ZOTEK® foams: retaining the attributes of high-performance polymers with the added benefits of (consistent) foaming T-FIT® high-performance insulation

ZOTEK® F fire, smoke, chemical performance foams ZOTEK® N high-temperature polyamide (nylon) foams ZOTEK® PEBA excellent kinetic-energy management T-FIT® technical insulation products

### Revenue

- 32% revenue growth, particularly from:
  - ZOTEK® PEBA in footwear
  - T-FIT® Clean in biotech and pharma markets
  - Offset by reduction in ZOTEK® F aviation destocking
- HPP, which offers the potential for accelerated growth and higher margins, now represents 19% of Group Revenue

### **Costs and Margin**

 Clear strategy to invest in opportunity for future growth and both R&D and sales development costs reflect this

HPP	Dec-17 £m	Dec-16 £m	% Change
Group revenue	13.15	9.99	32%
Segment profit pre- amortisation	3.16	2.48	27%
Segment profit post amortisation	3.16	2.48	27%
Segment profit margin	24%	25%	

- Portfolio of products, including early-stage developments (new and range extensions)
- T-FIT® product-line extensions launched, using a low-cost manufacturing process, targeting food, dairy and general process industries
- Successful progress on 3-D foaming

# HPP: a growth portfolio





### Technical Development of 3D foaming

- Capability to create solid 3D shape and retain this shape through the foaming process
- Large-scale plant trials ongoing with key sponsor
- Potentially applicable to all product lines but HPP gives clear benefit with less material to make final product

# T-FIT® technical insulation Development of product portfolio covering technical insulation requirements in regulated industries Local manufacturing strategy being developed KZKL in China operational Strategic partnership with Nike Investment in Croydon site to support demand expectations High level of resource, including R&D. Investment and alignment

# **Global Capacity**




# Capacity Development




### Global capacity management for local and global markets

- 2017 : operating at capacity
- 2018: USA "HP1" investment commissioned Q1
- 2019: USA "HP2" investment expected to commission H2
- 2019: UK "High-Temp LPs" expected to commission Q1-2

Bottleneck capacity increased by 45% over 2 years





for Block Foams

Geographic markets



+45%

Dec-17

Foam


Global Capacity Trend: annualised, indexed to 2017 bottleneck


# Financial Review




# **Key Performance Metrics**











# Income Statement



£million		Dec-17	Dec-16	% Change Reported
Group Revenue		70.15	57.38	22.3%
Group Profit		25.49	20.34	25.3%
Gross Profit Margin		36.3%	35.4%	
Adjusted Operating Profit	1,2	9.70	8.11	19.6%
Adjusted Profit before Tax	1,2	9.14	7.70	18.7%
Tax Charge		1.54	1.29	19.0%
Adjusted Profit after Tax	1,2	7.60	6.41	18.7%
Effective Tax Rate		20.4%	18.5%	
Adjusted EPS (p)	1,2	16.64	14.55	14.4%
Return on Capital	1,3	15.5%	14.0%	
Final Proposed DPS (p)		4.02	3.90	3.1%
Exceptional item		1.27	0.24	

- Exceptional item of £1.27m, following legal advice related to the effective closing of the scheme to future accrual of salaries.
- Effective tax rate above the Corporate rate of 19.25% due mainly to changes in US tax rates impacting losses carried forward
- Including the US investment assets not commissioned at 31.12.17, the return on capital increased from 11.94 to 12.07%

<sup>&</sup>lt;sup>1</sup> Before exceptional items


<sup>&</sup>lt;sup>2</sup> Excludes amortisation costs of acquired intangible assets

<sup>&</sup>lt;sup>3</sup> Ex US investment expansion

# Revenue Bridge



- 22% increase in revenue on a reported basis, 17% in constant currency
- · Growth across all business units



# Adjusted Operating Profit Bridge



- Foreign exchange impact £0.4m
- £3.4m of increased overhead to support pursuit of expansion strategy



# Investments




- HP1 in Kentucky, USA (previously a site with one low-pressure vessel), \$33m
  - Includes infrastructure and ancillary equipment for 3 high-pressure vessels
  - Includes 2 extrusion lines
  - Includes a 1<sup>st</sup> high-pressure vessel
  - Includes a 2<sup>nd</sup> high-pressure vessel to be commissioned when the Board considered appropriate
  - Adds over 20% global capacity
- HP2 in Kentucky, USA, \$9m
  - Includes ancillary equipment for 2<sup>nd</sup> high-pressure vessel
  - Includes an additional extrusion line
  - Adds over 20% global capacity
- High-temperature, low-pressure vessels in Croydon, £12m
  - Includes buildings and infrastructure, plus 2 vessels
  - Increases existing HPP capacity by a factor of six

# Net Debt & Covenants



- Net debt up £5.4m to £18.0m, vs £12.6m at Dec 2016
  - Net cash inflow from operations of £9.98m (up 57% vs 2016) used to support £11.4m of investment in property, plant, equipment and intangibles
- Net debt/EBITDA of 1.4 and interest cover 29x (as measured by banking agreement definitions)



- Zotefoams increasing growth expectations translate into capacity and working capital needs
- Close management of facilities and ratios to maintain strong balance sheet while supporting Zotefoams' growth strategy
- Zotefoams has increased its facilities to support growth during the period:
  - Lombard term loan of £7.5m, £4.5m drawn down at 31.12.17
  - Barclays RCF of £2.0m in March 2017, taking RCF to £10m
  - Barclays new term loan of £10m in March 2018
- In addition, Zotefoams has a fixed rate USD term loan of \$8m with Heritage Bank, USA

# Key Messages & Outlook



# Key Messages & Outlook



### Another record year for sales and profits

- 22% increase in Group revenue to a record £70.15m (2016: £57.38m)
  - 18% up in AZOTE® foams, with strong market mix improvements
  - 32% up in High-Performance Products (HPP)
  - 56% up in MuCell Extrusion
- 17% increase in Group revenue in constant currency
- 22% increase in reported PBT and exceptional items to a record £8.81m (2016: £7.23m)
- 8% increase in reported PBT after exceptional items to £7.55m (2016: £6.99m)

### An important period in the delivery of our strategy

- Completed US capacity expansion investment, which is now producing high-quality foam
- Entered into a strategic partnership with Nike, augmenting growth prospects in HPP
- Significant expenditure to deliver capacity for expected future growth
  - Commenced £12m low-pressure capacity investment in the UK
  - Approved further investment of \$9m to double high-pressure autoclave capacity in Kentucky, USA

**Outlook:** The year has started positively, with first quarter order volumes 8% higher than 2017 and an increased proportion of higher value HPP sales

# **Appendices**



# **Investment Case**



# Sustained high levels of organic growth with margin enhancement through product mix and operational gearing

autoclave capacity for block foam production (AZOTE® & ZOTEK®)

Flexible core

HPP growth rates significantly above AZOTE® foam, with superior margins

Investment in KY, USA will add to cost base initially but underpins growth potential



ZOTEK® (HPP) portfolio of products at different stages of development and market penetration MuCell® optionality: investment in customer base with long value tail

Sustainable high levels of organic growth due to innovative product portfolio and megatrend alignment

Downstream investment (ZMW, KZKL) to increase influence on supply chain and enhance margins

# Overview





# **Group Overview - Locations**



MuCell Extrusion HQ Woburn, MA, USA licences MuCell® technology to end users

Zotefoams Plc Croydon UK Block foam Main manufacturing site

> Phuket, Thailand Thai sales branch

Zotefoams Inc. Walton, KY, USA AZOTE® block foam expansion

Zotefoams Midwest Tulsa, OK, USA foam cutting

**Zotefoams Operations** Limited

AZOTE® Asia Limited Hong Kong Sales Joint Venture

Kunshan ZOTEK KingLai Co Ltd. Kunshan, PRC T-FIT® products manufacturing site

Page : 28

Key

Sales Office



**AZOTE®** 

**ZOTEK®** T-FIT® **MUCELL®** 

# Main markets & typical applications



### Packaging



AZOTE® ZOTEK® MuCell®

Luxury, fine art and museum Industrial protective and transit Aviation & aerospace Electronics Space station transit pods Consumer (food and household)

### **Transport**



AZOTE® ZOTEK®

Galley areas / window seals ECS (air ducting) Soft touch trim / close outs Composites panels Aircraft seats, seals Automotive seals, gaskets

### Industrial



AZOTE® T-FIT®

Seals and gaskets
Marine hoses and fenders
Clean room environments
High heat up to 205°C including
food processing & personal care
plants

# Sports & leisure



AZOTE® ZOTEK®

Athletic shoes, impact pads
Impact protection padding
Life jackets, swim floats,
Paddle boards, sports turf underlay

# Building & construction



**AZOTE®** 

Roof & wall insulation District heating pipe spacers Seals and gaskets, acoustic dampening

### Medical




**AZOTE®** 

Packaging
Prosthetics / orthoses
Buoyancy aids
Pads, seats and cushions


# Technology Block Foams




What sets us apart from competition is a unique, environmentally friendly process that uses nitrogen gas to produce a range of uniform closed-cell cross-linked foams.




Stage 1: High quality extrusion and cross-linking of solid polymeric sheet



Stage 2: Impregnation and saturation








Stage 3: Expansion


# MuCell® Process Technology



MUCELL® technology produces foam that performs like solid plastic. It creates microbubbles in the centre of plastic extrusions by injecting gas into the melt during manufacture.

- Lighter
- Greener
- Lower cost





Consumer

**Automotive** 

Packaging

Medical

Industrial

Aerospace

# Polymer (LDPE) Prices





# **Market Information**



Share price 495p (07/03/18)

Market Main Market

Ticker ZTF.L

Market cap. £220.0m

Ord. shares in issue 44,414,442



<sup>\*</sup> Source: Company Share Register (29/12/17)

# **Shareholder Profile\***

